SERPING1 and hereditary angioedema: This exploratory analysis suggested a trend toward greater efficacy and fewer adverse events with lanadelumab 150 mg Q2W versus C1-INH(IV) BIW 1000 IU and 500 IU in pediatric patients with HAE.